{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:00:08Z","timestamp":1781766008593,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI21\/01590"],"award-info":[{"award-number":["FIS PI21\/01590"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multidrug-resistant Gram-negative bacterial (MRGNB) infections represent a major public health threat. Cancer patients and, among them, hematological patients are most vulnerable to these infections. Gut colonization by MRGNB is a common phenomenon occurring during hospitalization and chemotherapy exposure. In the neutropenic phase that occurs after chemotherapy, MRGNB translocation occurs increasing patient\u2019s mortality. Fluoroquinolone prophylaxis with ciprofloxacin or levofloxacin efficacy is now being questioned due to the increase of incidence in MRGNB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A phase III randomized, controlled, clinical trial, open-label parallel-group with a 1:1 ratio, aimed to demonstrate the non-inferiority of oral fosfomycin versus oral ciprofloxacin for febrile neutropenia prevention in patients with acute leukemia (AL) or hematopoietic cell transplant (HSC) receptors. Weekly surveillance cultures are planned to detect gut colonization. Changes in fecal microbiome at the beginning and end of prophylaxis will also be analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial will provide evidence of the efficacy of an alternative drug to ciprofloxacin for febrile neutropenia prevention in high-risk hematological patients. The battery of planned microbiological studies will allow us to evaluate prospectively the microbiological safety of both pharmacological strategies in terms of the selection of MRGNB occurring in each arm. In addition, valuable information on the way in which each drug changes the fecal microbiome of the patients throughout the treatment will be generated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical trials NCT05311254, Registered on 5 April 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05311254?term=FOVOCIP&amp;cntry=ES&amp;draw=2&amp;rank=1\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05311254?term=FOVOCIP&amp;cntry=ES&amp;draw=2&amp;rank=1<\/jats:ext-link>. Protocol version: 3.0, dated 20 May 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07702-5","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T12:02:39Z","timestamp":1698408159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients\u2014efficacy and microbiologic safety"],"prefix":"10.1186","volume":"24","author":[{"given":"Ainhoa Fern\u00e1ndez","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Lav\u00edn-Alconero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L\u00f3pez","family":"de Ugarriza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Sol\u00e1n","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C\u00e1ceres","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel Bergua","family":"Burgu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Izquierdo","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Julia Gonz\u00e1lez","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Polo","family":"Zarzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karem","family":"Humala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Calabuig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n Cuesta","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Mar Garc\u00eda-Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Fern\u00e1ndez","family":"Verdugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Fern\u00e1ndez","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-513X","authenticated-orcid":false,"given":"Teresa","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"7702_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56-93.","journal-title":"Clin Infect Dis"},{"key":"7702_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","volume":"142","author":"A Gafter-Gvili","year":"2005","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979\u201395.","journal-title":"Ann Intern Med"},{"key":"7702_CR3","first-page":"1720","volume":"67","author":"MJ Satlin","year":"2018","unstructured":"Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, et al. Colonization with levofloxacin-resistant extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2018;67:1720\u20138.","journal-title":"Clin Infect Dis"},{"key":"7702_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/bmt.2014.231","volume":"50","author":"C Girmenia","year":"2015","unstructured":"Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50:282\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"7702_CR5","doi-asserted-by":"publisher","first-page":"e0210991","DOI":"10.1371\/journal.pone.0210991","volume":"14","author":"O Ballo","year":"2019","unstructured":"Ballo O, Tarazzit I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA, et al. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy. PLoS ONE. 2019;14:e0210991.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"7702_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1469-0691.12427","volume":"20","author":"E Tacconelli","year":"2014","unstructured":"Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1\u201355.","journal-title":"Clin Microbiol Infect"},{"key":"7702_CR7","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.3390\/jcm8111985","volume":"8","author":"C Casta\u00f1\u00f3n","year":"2019","unstructured":"Casta\u00f1\u00f3n C, Fern\u00e1ndez Moreno A, Fern\u00e1ndez Verdugo AM, Fern\u00e1ndez J, Mart\u00ednez Ortega C, Alaguero M, et al. The value of adding surveillance cultures to fluoroquinolone prophylaxis in the management of multiresistant gram negative bacterial infections in acute myeloid leukemia. JCM. 2019;8:1985.","journal-title":"JCM"},{"key":"7702_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12879-022-07154-3","volume":"22","author":"I Torres","year":"2022","unstructured":"Torres I, Huntley D, Tormo M, Calabuig M, Hern\u00e1ndez-Boluda JC, Terol MJ, et al. Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. BMC Infect Dis. 2022;22:172.","journal-title":"BMC Infect Dis"},{"key":"7702_CR9","doi-asserted-by":"crossref","unstructured":"Gudiol C, Aguilar-Guisado M, Azanza JR, et al. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enferm Infecc Microbiol Clin. 2020;38(4):174\u201381.","DOI":"10.1016\/j.eimc.2019.01.013"},{"key":"7702_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bbmt.2014.01.030","volume":"20","author":"E Holler","year":"2014","unstructured":"Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:640\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7702_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/cid\/ciy153","volume":"67","author":"H Hakim","year":"2018","unstructured":"Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, et al. Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia. Clin Infect Dis. 2018;67:541\u20138.","journal-title":"Clin Infect Dis"},{"key":"7702_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.clinthera.2014.04.013","volume":"36","author":"DJ Wojenski","year":"2014","unstructured":"Wojenski DJ, Barreto JN, Wolf RC, Tosh PK. Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series. Clin Ther. 2014;36:976\u201381.","journal-title":"Clin Ther"},{"key":"7702_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/0959-8049(92)90138-R","volume":"28A","author":"JP Donnelly","year":"1992","unstructured":"Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer. 1992;28A:873\u20138.","journal-title":"Eur J Cancer."},{"key":"7702_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29:321\u201347.","journal-title":"Clin Microbiol Rev"},{"key":"7702_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.6000\/1929-6029.2015.04.03.7","volume":"4","author":"Y Liu","year":"2015","unstructured":"Liu Y, De A. Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. IJSMR. 2015;4:287\u201395.","journal-title":"IJSMR"},{"key":"7702_CR16","doi-asserted-by":"crossref","unstructured":"Clerici D, Galli L, Greco R, et al. Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an\u00a0endemic country for carbapenem-resistant GNB. Blood Adv. 2023;7(9):1621\u201334.","DOI":"10.1182\/bloodadvances.2022008226"},{"key":"7702_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1086\/428732","volume":"40","author":"S Reuter","year":"2005","unstructured":"Reuter S, Kern WV, Sigge A, D\u00f6hner H, Marre R, Kern P, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40:1087\u201393.","journal-title":"Clin Infect Dis"},{"key":"7702_CR18","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00520-017-4040-x","volume":"26","author":"T Zapolskaya","year":"2018","unstructured":"Zapolskaya T, Perreault S, McManus D, Topal JE. Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies. Support Care Cancer. 2018;26:1979\u201383.","journal-title":"Support Care Cancer"},{"key":"7702_CR19","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1128\/JCM.02369-14","volume":"52","author":"JP Ridgway","year":"2014","unstructured":"Ridgway JP, Peterson LR, Thomson RB, Miller BA, Wright M-O, Schora DM, et al. Sensitivity of surveillance testing for multidrug-resistant Gram-negative bacteria in the intensive care unit. J Clin Microbiol. 2014;52:4047\u20138.","journal-title":"J Clin Microbiol"},{"key":"7702_CR20","first-page":"403","volume":"55","author":"S Hahn","year":"2012","unstructured":"Hahn S. Understanding noninferiority trials. Korean. J Pediatr. 2012;55:403.","journal-title":"J Pediatr"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07702-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T12:04:48Z","timestamp":1698408288000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07702-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7702"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07702-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this trial, which is in compliance with the Helsinki Declaration and in agreement with the SPIRIT statement, was obtained for the Ethics Committee of Principado de Asturias dated 26 August 2021 to corresponds to version 2.1 (19 August 2021). The protocol amendment version 3.0 was approved by the AEMPS on 27 May 2022.The subsequent informed consent form will be obtained from all the participants. According with the current legislation regarding to clinical trials (RD 1090\/2015), the AEMPS will be notified of the start of the clinical trial. The obtained personal data and biological samples of all patients will be treated with confidentiality and security, in accordance with the regulations based on Regulation (EU) 2016\/679 and Law 14\/2007 on Biomedical Research.The clinical trial has been classified as a low intervention level clinical trial (ECBNI) and is, therefore, in accordance with the current legislation RD1090\/2015, which specifies that low intervention level studies do not need to be covered by an insurance contract or financial guarantee, if they are covered by the individual or collective professional liability insurance or equivalent financial guarantee of the health site where the clinical trial is carried out. This is the responsibility of each site and not of the sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"694"}}